In a newly reported randomized controlled investigation assessing topical therapies for mild-to-moderate plaque psoriasis, adding a specialized ceramide-containing repair and moisturizing cream to standard calcipotriol treatment failed to produce a statistically significant improvement in the primary clinical endpoint compared to calcipotriol monotherapy. Conducted in an adult outpatient cohort, the trial evaluated whether physiological barrier restoration via a triple-ceramide formulation could augment the therapeutic efficacy of a established topical vitamin D analog over an eight-week evaluation period. The study authors reported that the change from baseline in the total Psoriasis Area and Severity Index score at day 56 did not significantly separate the experimental combination regimen from active monotherapy. Although both study arms demonstrated robust within-group clinical clearance across the two-month intervention, the formal between-group analysis of the prespecified primary efficacy measure showed that adjunctive topical lipid supplementation did not deliver superior reduction in total cutaneous lesion extent or scaling compared to standard calcipotriol alone.
Plaque psoriasis represents a persistent inflammatory dermatosis driven by reciprocal interactions between immune cascade activation, abnormal epidermal keratinocyte proliferation, and structural disruptions of the stratum corneum permeability barrier. Standard outpatient management for patients presenting with mild-to-moderate disease involvement relies heavily on topical antipsoriatic agents, prominently including synthetic vitamin D3 derivatives such as calcipotriol alongside topical corticosteroids.
The investigative team formulated and executed a single-center, parallel-group, randomized clinical trial at Shanghai Skin Disease Hospital, securing formal protocol approval from the institutional ethics committee under approval number 2022-15 and prospectively logging the trial design with the Chinese Clinical Trial Registry under identifier ChiCTR2200063795. To establish sample size parameters, investigators conducted power calculations assuming a two-sided alpha threshold of 0.05 and 90 percent statistical power based on historic PASI variance parameters of 5.36 plus or minus 0.89 versus 4.45 plus or minus 1.01 documented in prior published literature. While standard sample size modeling through OpenEPI indicated a baseline requirement of at least 25 participants per operational arm, the protocol initially planned for 60 participants to compensate for potential follow-up attrition. Ultimately, investigators enrolled and randomized 80 consenting adult patients in a strict one-to-one allocation ratio, assigning 40 participants to the active intervention arm and 40 participants to the active control monotherapy arm.
Patient selection adhered to tightly controlled diagnostic and therapeutic boundaries to ensure an accurate clinical sample of mild-to-moderate plaque psoriasis. Eligible participants were men and women aged 18 years or older presenting with an overall affected body surface area of 10 percent or less and a baseline total Psoriasis Area and Severity Index score not exceeding 10. The trial protocol excluded individuals who had received prior systemic biologic therapies capable of influencing psoriatic pathophysiology, as well as anyone who had undergone phototherapy, photochemotherapy, or systemic antipsoriatic interventions including oral retinoids, systemic corticosteroids, or immunosuppressive drugs within four weeks prior to enrollment. Furthermore, prospective candidates were barred if they had used topical antipsoriatic formulations, including topical corticosteroids or topical vitamin D derivatives, within two weeks preceding study initiation. Investigators also excluded candidates presenting with predominant involvement of sensitive regional zones such as the scalp, face, or genitalia, alongside pregnant or lactating individuals, patients with histories of severe hepatic, renal, cardiac, or hematologic dysfunction, and individuals with concurrent autoimmune dermatoses such as lupus erythematosus or pemphigus.
The active treatment phase spanned 56 consecutive days, structured around four formal clinical monitoring visits conducted at baseline day 0, day 7 plus or minus one day, day 28 plus or minus two days, and day 56 plus or minus three days. Participants allocated to the control cohort applied commercial calcipotriol cream, manufactured as Daivonex by LEO Laboratories Limited, topically to their active psoriatic lesions twice daily, once in the morning and once in the evening. Participants randomized to the investigational intervention arm followed the identical twice-daily topical calcipotriol schedule but were instructed to apply an adjunctive barrier repair cream containing ceramides EOP, NP, and AP exactly 30 minutes following each calcipotriol application. Alongside clinician-rated cutaneous scoring, investigators conducted comprehensive biophysical skin barrier examinations at every scheduled visit, tracking transepidermal water loss, the water content of the stratum corneum, skin surface pH, the Erythema Index E value, local blood flow dynamics, and cutaneous lipid structure alterations.
Of the 80 randomized patients entering the protocol, 70 completed all scheduled evaluations through day 56, reflecting an overall study retention rate of 87.5 percent, while 10 patients were lost to follow-up across the eight-week timeline. To manage participant dropouts and data integrity, investigators delineated distinct analytic populations, including a safety set of all dosed participants, a full analysis set comprising 65 patients who had received study medication and contributed post-baseline assessments, and a per-protocol set consisting of 64 participants who completed the trial without major eligibility violations. Notably, participant attrition showed an asymmetric distribution, with seven individuals lost to follow-up in the combination intervention group compared to three individuals in the monotherapy control group. Within the full analysis set, 30 participants represented the intervention arm and 35 participants represented the control arm, with missing day 56 primary outcome figures imputed using the last observation carried forward method.
Statistical evaluation of the primary efficacy outcome revealed no significant divergence between the experimental arms at the primary day 56 study endpoint. In the full analysis set with last observation carried forward imputation, the mean reduction from baseline in total PASI score was negative 2.41 plus or minus 1.31 in the adjunctive ceramide intervention group compared to negative 2.18 plus or minus 2.23 in the calcipotriol monotherapy control group, generating a non-significant between-group p-value of 0.948. Absolute total PASI values at day 56 similarly exhibited no statistically meaningful variation between cohorts, yielding a p-value of 0.169. Parallel sensitivity analyses performed on observed cases within both the full analysis set and the per-protocol population corroborated this absence of divergence at days 7, 28, and 56. Although categorical response thresholds indicated numerically higher proportions of participants achieving PASI 50 and PASI 75 reductions in the adjunctive arm, none of these proportional comparisons achieved statistical significance, thereby demonstrating that adjunctive ceramide application did not enhance primary lesion clearance beyond calcipotriol alone.
In contrast to the neutral primary endpoint, secondary and exploratory analyses documented transient advantages in physician-assessed clearance and early physiological barrier recovery. Clinician evaluation utilizing the Physician’s Global Assessment demonstrated a statistically significant treatment difference favoring the combination regimen at day 56, with greater overall disease resolution recorded in the intervention arm across both the full analysis set with a nominal p-value of 0.034 and the per-protocol set with a nominal p-value of 0.032. Furthermore, instrument-measured transepidermal water loss revealed an accelerated barrier stabilization signal by day 7, with a median change of negative 1.06 in the ceramide arm compared to positive 4.49 in the monotherapy arm, yielding nominal p-values of 0.035 in the full analysis set and 0.043 in the per-protocol set. By day 56, this evaporative water loss difference between treatment groups had attenuated to statistical equivalence, whereas stratum corneum water content at day 56 showed significantly greater improvement in the intervention arm in the full analysis set at nominal p equals 0.039, though the corresponding per-protocol comparison narrowly missed formal significance at p equals 0.056.
Patient-reported functional outcomes captured through the Dermatology Life Quality Index echoed this pattern of early symptomatic divergence followed by late-stage convergence. Participants administering the adjunctive ceramide cream experienced significantly superior reductions in quality-of-life impairment at day 7 with a nominal p-value of 0.013 and at day 28 with a nominal p-value of 0.011 within the full analysis set. However, by the concluding day 56 visit, the numerical differences in life quality scores between the two cohorts had converged, displaying no remaining statistically significant contrast as active calcipotriol monotherapy brought both patient groups toward substantial overall symptom resolution and quality-of-life stabilization. Regarding treatment safety and tolerability, investigators recorded no serious adverse events throughout the trial period. The predominant reported adverse symptom consisted of mild-to-moderate cutaneous pruritus, which appeared at a slightly elevated frequency in the combination therapy arm. Additionally, investigators documented a single isolated case of systemic erythema, which was clinically evaluated and attributed to calcipotriol rather than the investigational barrier moisturizer.
Interpreting these experimental findings requires careful contextualization within the framework of trial design constraints and methodological limitations noted by the study authors. Because the trial tested numerous exploratory biophysical parameters, regional anatomical indices, and intermediate visit milestones without implementing formal statistical adjustments for multiple testing multiplicity, nominal p-values must be regarded as exploratory and hypothesis-generating rather than definitive proof of efficacy. Moreover, the investigative team emphasized that the study was conducted at a single medical center with a relatively modest sample size, an eight-week observation horizon, and unequal participant attrition that saw more than double the dropout rate in the intervention arm. The study cohort was explicitly restricted to adult outpatients with mild-to-moderate plaque psoriasis exhibiting localized surface involvement of 10 percent or less, precluding the direct generalization of these results to severe psoriatic phenotypes, pediatric patients, or other distinct clinical variants. While adjunctive ceramide skincare appears to accelerate early barrier hydration and provide modest symptomatic comfort, the authors concluded that larger multicenter trials with longer durations are required to establish whether topical lipid supplementation provides durable clinical utility in routine antipsoriatic management.
Subject of Research: Clinical evaluation of adjunctive ceramide cream combined with topical calcipotriol for mild-to-moderate plaque psoriasis
Article Title: Adjunctive Efficacy of a Ceramide-Containing Repair and Moisturizing Cream in the Management of Mild-to-Moderate Plaque Psoriasis
Article References: Gao, Y., Jiang, Y., Shen, Z., Wang, Y., & Shi, Y. (2026). Adjunctive Efficacy of a Ceramide-Containing Repair and Moisturizing Cream in the Management of Mild-to-Moderate Plaque Psoriasis. Dermatology and Therapy. https://doi.org/10.1007/s13555-026-01977-7
Image Credits: AI Generated
DOI: 10.1007/s13555-026-01977-7
Keywords: plaque psoriasis, calcipotriol, ceramides, skin barrier function, Psoriasis Area and Severity Index, transepidermal water loss, stratum corneum hydration, Physician Global Assessment, Dermatology Life Quality Index, randomized controlled trial, topical therapy, dermatology, pruritus, emollient therapy, epidermal barrier repair, Daivonex
News Source: Ophelia Keating. (November 12, 2026). Adjunctive Ceramide Moisturizer Misses Primary Psoriasis Endpoint in Controlled Trial. Scienmag.



